Abvc Biopharma, Inc. $ABVC

What the company doesAI summary of filing

ABVC Biopharma is an early-stage biotechnology company with a pipeline of seven drugs and one medical device under development, all licensed from related parties. The company generates revenue through outlicensing intellectual properties and providing contract development and manufacturing organization (CDMO) services via its subsidiary BioKey. ABVC focuses on developing botanical drugs for central nervous system and oncology/hematology diseases by identifying promising candidates from research institutions in the Asia-Pacific region, then conducting clinical trials through partnerships with academic medical centers in the United States, Taiwan, and Australia. Upon successful Phase II trials, the company seeks partnerships with larger pharmaceutical companies to complete Phase III studies and commercialize products following regulatory approval. [10-K 2026-03-03]

Segments: CNS drugs (ABV-1504, ABV-1505, ABV-1601), Oncology drugs (ABV-1702, ABV-1703, ABV-1501), Medical device (ABV-1701 Vitargus), CDMO services and dietary supplements (maitake mushroom)